3 citations
,
February 2022 in “Rheumatology” Baricitinib was effective in treating a patient with dermatomyositis and hair loss.
26 citations
,
October 2020 in “Pediatric Dermatology” Oral tofacitinib may effectively treat hair loss in children with alopecia areata.
16 citations
,
May 2022 in “New England Journal of Medicine” Baricitinib is not very effective for severe alopecia areata.
185 citations
,
June 2014 in “Journal of Investigative Dermatology” A man with severe hair loss and skin disease regrew his hair with no side effects after taking tofacitinib.
22 citations
,
March 2017 in “Journal of the Formosan Medical Association” The guidelines help doctors manage skin problems from certain cancer treatments to improve patients' lives.
November 2023 in “SKIN The Journal of Cutaneous Medicine”
July 2025 in “Frontiers in Medicine” Baricitinib successfully regrew hair in an 8-year-old boy with alopecia totalis linked to a KRT74 gene variant.
September 2023 in “Acta dermato-venereologica” Tofacitinib is a safe and effective treatment for hair loss in children with Alopecia Areata.
Baricitinib works better than methotrexate for severe alopecia areata.
The combination therapy effectively improved acne keloidalis nuchae.
25 citations
,
October 2019 in “JAAD Case Reports” Baricitinib helped a woman with severe hair loss regrow almost all her hair without side effects.
April 2024 in “JEADV clinical practice” Upadacitinib significantly improved both rheumatoid arthritis and alopecia areata in a patient.
1 citations
,
February 2025 in “International Journal of Dermatology” Abrocitinib may effectively treat Lichen Planopilaris.
51 citations
,
May 2008 in “Mycoses” Terbinafine HCl nail solutions with DDAIP HCl are more effective than current treatments for nail infections.
2 citations
,
December 2022 in “PNAS nexus” SCD-153 shows promise as an effective topical treatment for alopecia areata.
2 citations
,
September 2022 in “Dermatologic Therapy” Tofacitinib is a promising treatment for severe alopecia areata, with many patients experiencing complete or partial hair regrowth.
November 2024 in “Skin Appendage Disorders” Clinicians should consider individual factors and communicate risks and benefits when prescribing ritlecitinib for adolescent alopecia areata.
September 2023 in “JAAD case reports” A man developed oral hairy leukoplakia while on baricitinib, a medication for alopecia and arthritis, and doctors should watch for such side effects.
July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively improves hair regrowth and physician satisfaction in severe alopecia areata over time.
January 2024 in “Skin Research and Technology” Oral tofacitinib may be an effective future treatment for children with severe alopecia areata, but more research is needed.
1 citations
,
December 2024 in “Archives of Iranian Medicine” Tofacitinib may help treat Lichen Planopilaris, but more research is needed.
January 2024 in “Faculty of 1000 Research Ltd” Tazarotene gel may be more effective for acne than adapalene gel.
1 citations
,
March 2004 in “Journal of the American Academy of Dermatology” ZD1839, a cancer drug, can cause mild skin rashes that are treatable without stopping the medication.
13 citations
,
September 2022 in “Materials & design” The new patch for treating mouth sores releases medicine slowly, sticks well, and helps healing without the side effects of current creams.
March 2026 in “British Journal of Dermatology” Deucravacitinib did not significantly improve hair regrowth in alopecia areata patients.
October 2025 in “Dermatology and Therapy” Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.
4 citations
,
March 2012 in “Annals of oncology” New treatment with green tea polyphenols and nicotinamide improves skin problems from cancer therapy.
February 2006 in “Journal of The American Academy of Dermatology” Terbinafine is more effective than itraconazole for toenail fungus, especially in older patients, and debridement improves its effectiveness.
May 2026 in “Journal of Neurosciences in Rural Practice” Tofacitinib may cause nerve damage in the brain, so monitor for neurological symptoms.
March 2017 in “Current dermatology reports” Topical JAK inhibitors can effectively treat alopecia areata and vitiligo by modulating immune responses.